Resistance to lysis by cytotoxic T cells: A dominant effect in metastatic mouse prostate cancer cells

Cancer Research

Volumn 60, Issue 7, 2000, Pages 1927-1933

  Lee, Hon Man ^a,b   Timme, Terry L ^a,b   Thompson, Timothy C ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; GAMMA INTERFERON; PROTEASOME;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; IMMUNOGENICITY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; CELL FUSION; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-2; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034109776     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Thompson, T. C., Souihgate, J., Kitchener, G., and Land, H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell, 56: 917-930, 1989.
3. Thompson, T. C., Park, S. H., Timme, T. L., Ren, C., Eastham, J., Donehower, L., Bradley, A., Kadmon, D., and Yang, G. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene. 10: 869-879, 1995.
4. Thompson, T. C. Growth factors and oncogenes in prostate cancer. Cancer Cells (Cold Spring Harbor), 2: 345-354, 1990.
5. Thompson, T. C., Timme, T. L., and Sehgal, I. Oncogenes, growth factors, and hormones in prostate cancer. In: R. B. Dickson and D. S. Salomon (eds.), Hormones and Growth Factors in Development and Neoplasia. New York: John Wiley & Sons, Inc., 1997.
6. Eastham, J. A., Stapleton, A. M. F., Gousse, A. E., Timme, T. L., Yang, G., Slawin, K. M., Wheeler, T. M., Scardino, P. T., and Thompson, T. C. Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res., 1: 1111-1118, 1995.
7. Thompson, T. C., Timme, T. L., and Sehgal, I. The role of p53 in prostate cancer progression. In: J. G. Former and P. A. Sharp (eds.). Accomplishment in Cancer Research 1996. Philadelphia: Lippincott-Raven, 1997.
8. Navone, N. M., Troncoso, P., Pisters, L. L., Goodran, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C., and Conti, C. J. p53 accumulation and gene mutation in the progression of human prostate cancer. J. Natl. Cancer Inst., 84: 1657-1669, 1993.
9. Hall, S. J., and Thompson, T. C. Spontaneous but not experimental metastatic activities differentiate primary tumor-derived versus metastasis-derived mouse prostate cancer cell lines. Clin. Exp. Metastasis, 15: 630-638, 1997.
10. Maccubbin, D. L., Mace, K. F., Ehrke, M. J., and Mihich, E. Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res., 49: 4216-4224, 1989.
11. Janik, P., Briand, P., and Hartmann, N. R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res., 35: 3698-3704, 1975.
12. Matzinger, P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods, 145: 185-192, 1991.
13. Sehgal, I., Baley, P. A., and Thompson, T. C. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res., 56: 3359-3365, 1996.
14. Sanda, M. G., Restifo, N. P., Walsh, J. C., Kawakami, Y., Nelson, W. G., Pardoll, D. M., and Simons, J. W. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst., 87: 280-285, 1995.
15. Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Meyer, T., Tampe, R., Momburg, F., and Huber, C. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res., 56: 1756-1760, 1996.
16. Khanna, R. Tumour surveillance: missing peptides and MHC molecules. Immunol. Cell Biol., 76: 20-26, 1998.
17. Rees, R. C., and Mian, S. Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol. Immunother., 48: 374-381, 1999.
18. Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F., and Stern, P. L. Natural history of HLA expression during tumor development. Immunol. Today, 14: 491-499, 1993.
19. Seliger, B., Dunn, T., Schwenzer, A., Casper, J., Huber, C., and Schmoll, H. J. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their up-regulation by IFN-γ. Scand. J. Immunol., 46: 625-632, 1997.
20. Seliger, B., Harders, C., Lohmann, S., Momburg, F., Urlinger, S., Tampe, R., and Huber, C. Down-regulation of MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur. J. Immunol., 28: 122-133, 1998.
21. McConkey, D. J., Greene, G., and Pettaway, C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res., 56: 5594-5599, 1996.
22. Rokhlin, O. W., Hostager, B. S., Bishop, G. A., Sidorenko, S. P., Glover, R. A., Gudkov, A. V., and Cohen, M. B. Dominant nature of the resistance to Fas- and tumor necrosis factor-α-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res., 57: 3941-3943, 1997.
23. Rokhlin, O. W., Glover, R. A., and Cohen, M. B. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res., 58: 5870-5875, 1998.
24. Hitoshi, Y., Lorens, J., Kitada, S-I., Fisher, J., LaBarge, M., Ring, H. Z., Francke, U., Reed, J. C., Kinoshita, S., and Nolan, G. P. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity, 8: 461-471, 1998.
25. Shresta, S., Pham. C. T. N., Thomas, D. A., Graubert, T. A., and Ley, T. J. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol., 10: 581-587, 1998.
26. Shresta, S., Russell, J. H., and Ley, T. J. Mechanisms responsible for granzyme B-independent cytotoxicity. Blood. 89: 4085-4091, 1997.
27. Muller, C., and Tschopp, J. Resistance of CTL to perforin-mediated lysis. Evidence for a lymphocyte membrane protein interacting with perform. J. Immunol., 153: 2470-2478, 1994.
28. Sarin, A., Williams, M. S., Alexander-Miller, M. A., Berzofsky, J. A., Zacharchuk, C. M., and Henkart, P. A. Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases. Immunity, 6: 209-215, 1997.
29. Sarin, A., Haddad, E. K., and Henkart, P. A. Caspase dependence of target cell damage induced by cytotoxic lymphocytes. J. Immunol., 161: 2810-2816, 1998.
30. Andrade, F., Roy, S., Nicholson, D., Thornberry, N., Rosen, A., and Casciola-Rosen, L. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-rnduced apoptosis. Immunity, 8: 451-460, 1998.
31. Naftzger, C., and Houghton, A. N. Tumor immunology. Curr. Opin. Oncol., 3: 93-99, 1991.
32. Van den Eynde, B. J., and van der Bruggen, P. T-cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
33. Wang, R. F., and Rosenberg, S. A. Human tumor antigens for cancer vaccine development. Immunol. Rev., 170: 85-100, 1999.
34. Jager, E., Jager, D., and Knuth, A. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev., 18: 143-150, 1999.